Fate Therapeutics — Biomedical Watch V2

Traitements4programmes

Essais2liés

Publications0liées

SourceDBlocale

Traitements

4

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
FT819The primary objective of this trial is to evaluate the efficacy and safety of FT819, comprised of allogeneic T cells that express a CD19-targeted CAR, following bendamustine administration in participants with refractory moderate-to-severe lupus nephritis, as assessed by the proportion of participants who achieve complete renal response (CRR) at Week 26.	Lupus	Phase 2	Immunomodulation	United States	À vérifier
FT839The primary objectives of this trial are to evaluate the safety and tolerability and to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose of FT839 with or without rituximab and/or background therapy and/or conditioning therapy.	Lupus, Myopathies	Phase 1/2	À vérifier	United States	À vérifier
FT819The primary objective of this trial is to evaluate the efficacy and safety of FT819, comprised of allogeneic T cells that express a CD19-targeted CAR, following bendamustine administration in participants with refractory moderate-to-severe lupus nephritis, as assessed by the proportion of participants who achieve complete renal response (CRR) at Week 26.	Lupus	Phase 2	Immunomodulation	United States	À vérifier
FT839The primary objectives of this trial are to evaluate the safety and tolerability and to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose of FT839 with or without rituximab and/or background therapy and/or conditioning therapy.	Lupus	Phase 1/2		United States	À vérifier

Essais cliniques

2

Molécule	Indication / population	Phase	NCT	Titre	Statut
FT839	Lupus	Phase 1/2	NCT07800871	FT839 in Autoimmune Diseases	RECRUITING
FT819	Lupus	Phase 2	NCT07570862	RECLAIM-LN — A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis	RECRUITING

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.